Placebo1

DIETARY_SUPPLEMENT3 trials

Sponsors

Clinical Nutrition Research Center, Illinois Institute of Technology, Laboratorios Sophia S.A de C.V., Innovent Biologics (Suzhou) Co. Ltd.

Conditions

Insulin ResistanceMetabolic DiseaseNon-Squamous Non-Small Cell Lung CancerNutritional DiseasePrimary Open-angle Glaucoma

Phase 3

PRO-122 Versus Concomitant Therapy in Subjects With Uncontrolled Primary Open-angle Glaucoma (PRO-122LATAM)

TerminatedNCT03193333

Laboratorios Sophia S.A de C.V.Primary Open-angle Glaucoma

Start: 2017-11-06End: 2024-10-30Updated: 2025-03-06

Sintilimab ± IBI305 Plus Chemotherapy (Pemetrexed + Cisplatin) for EGFRm + Locally Advanced or Metastasis Non-Squamous NSCLC Patients After EGFR-TKI Treatment Failure

CompletedNCT03802240

Innovent Biologics (Suzhou) Co. Ltd.Non-Squamous Non-Small Cell Lung Cancer

Start: 2019-07-11End: 2023-06-30Updated: 2023-11-27

Unknown Phase

Effect of 6-week Strawberry Supplementation on Insulin Action (STR2)

CompletedNCT01457612

Clinical Nutrition Research Center, Illinois Institute of TechnologyInsulin Resistance, Metabolic Disease, Nutritional Disease

Start: 2011-10-01End: 2013-03-01Updated: 2023-02-08

Related Papers

Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial.

2023-05-05145 citations

Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial.

2022-07-28168 citations